Status:
RECRUITING
Perceptual Abnormalities and Their Malleability in BDD
Lead Sponsor:
Centre for Addiction and Mental Health
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
University of Alabama at Birmingham
Conditions:
Body Dysmorphic Disorder
Eligibility:
All Genders
18-40 years
Phase:
NA
Brief Summary
A core symptom of body dysmorphic disorder (BDD) is perceptual distortions for appearance, which contributes to poor insight and delusionality, limits engagement in treatment, and puts individuals at ...
Detailed Description
Individuals with body dysmorphic disorder (BDD) misperceive specific aspects of one's own appearance to be conspicuously flawed or defective, despite these being unnoticeable or appearing minuscule to...
Eligibility Criteria
Inclusion
- Body dysmorphic disorder: Inclusion:
- males or females
- ages 18-40
- meet Diagnostic and Statistical Manual-5 (DSM-5) criteria for Body Dysmorphic Disorder
- have a Body Dysmorphic Disorder version of the Yale-Brown Obsessive-Compulsive Disorder Scale (BDD-YBOCS) score of ≥20
- primary appearance concerns of the face or head area
- medication naïve or medication free for at least 8 weeks prior to enrollment
- Subclinical body dysmorphic disorder: Inclusion:
- males or females
- ages 18-40
- have a score on the Dysmorphic Concern Questionnaire of ≥8 \[1 standard deviation (STD) above population norms\] - primary appearance concerns of the face or head area
- medication naïve or medication free for at least 8 weeks prior to enrollment
- Healthy controls: Inclusion
- Healthy males and females from any racial or ethnic background - ages 18-40
- have a score on the Dysmorphic Concern Questionnaire of \<8
Exclusion
- Body dysmorphic disorder: Exclusion
- concurrent major Axis I disorders including substance use disorders, aside from anxiety disorders or depressive disorders, as these comorbidities are very common and the sample would otherwise be non-representative; however BDD must be the primary diagnosis.
- lifetime: bipolar disorder or psychotic disorder.
- psychotropic medications, aside from a short half-life sedative/hypnotic for insomnia, or a short half-life benzodiazepine as needed for anxiety but not exceeding a frequency of 3 doses in one week and not to be taken on the days of the training or MRI scan
- current cognitive-behavioral therapy
- Exclusion:
- Subclinical body dysmorphic disorder: Exclusion
- meet full DSM-5 criteria for Body Dysmorphic Disorder
- current Axis I disorders including substance use disorders
- lifetime: bipolar disorder or psychotic disorder
- psychotropic medications, aside from a short half-life sedative/hypnotic for insomnia, or a short half-life benzodiazepine as needed for anxiety but not exceeding a frequency of 3 doses in one week and not to be taken on the days of the training or MRI scan
- current cognitive-behavioral therapy
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
146 Patients enrolled
Trial Details
Trial ID
NCT04373629
Start Date
December 1 2020
End Date
June 1 2026
Last Update
November 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M6J 1H3